What is cancer?

Cancer is a disease in which some of the body’s cells grow uncontrollably and spread to other parts of the body. 

Cancer can start almost anywhere in the human body, which is made up of trillions of cells. Normally, human cells grow and multiply (through a process called cell division) to form new cells as the body needs them. When cells grow old or become damaged, they die, and new cells take their place.

Sometimes this orderly process breaks down, and abnormal or damaged cells grow and multiply when they shouldn’t. These cells may form tumors, which are lumps of tissue. Tumors can be cancerous or not cancerous (benign). 

Nuformix plc (LON:NFX) is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology using drug repurposing.

Click to view all articles for the EPIC:
Or click to view the full company profile:
Facebook
X
LinkedIn
Nuformix plc

More articles like this

Nuformix plc

Nuformix Plc Receives Second NXP001 Milestone Payment from Oxilio

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced that the Company has achieved the second milestone according to its updated NXP001 exclusive licensing agreement with Oxilio

Nuformix plc

Nuformix hosting online Q&A session on 13 June 2023

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced that the Company’s Executive Director, Dr Dan Gooding, will be hosting an online Q&A session at 5.30

Nuformix plc

Nuformix appoints Kreston Reeves as auditor

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced the appointment of Kreston Reeves LLP as auditor to the Company. The appointment of Kreston Reeves

Nuformix plc

Nuformix delighted with NXP002 study results

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced the following update regarding the Company’s NXP002 programme, a proprietary new form of tranilast, being developed as a

Nuformix plc

Nuformix updates on the NXP002 programme for treatment of IPF

Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced the following update regarding the Company’s NXP002 programme, a proprietary new form of tranilast, being developed as a